Connect with us

Science

Best Penny Stocks to Buy Today? 3 For Your Watchlist

Should you add these penny stocks to your watchlist this month?
The post Best Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

3 Penny Stocks to Add to Your Watchlist Today 

Following a bullish few weeks for penny stocks and blue chips, we are beginning to see signs of Omicron-related fears settle in. Yesterday, news came out showing that the U.S. had hit 1 million cases of Covid per day. And while we knew this was coming, it is once again, sending shockwaves through the stock market. 

During early trading, stock futures fell slightly despite surging job growth and hope for a bullish new year. When it comes to penny stocks, investors have to understand that events going on will always have a large effect on how small-caps trade. In addition, we tend to see volatility be substantially higher than that of blue chips. But, this volatility is also something that many investors look for as it offers the potential to see sizable short-term gains (and losses). 

[Read More] Hot Penny Stocks For 2022 To Buy For Under $2

Regardless, it is crucial to have a thorough and well-thought-out trading strategy. This strategy should align with what is going on in the world and should take advantage of that movement. Considering that there are many fluctuations occurring with penny stocks right now, let’s take a look at three that could be worth watching. 

3 Penny Stocks to Watch Right Now 

  1. Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT
  2. Castlight Health Inc. (NYSE: CSLT
  3. Senseonics Holdings Inc. (NYSE: SENS

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) 

One of, if not the biggest gainer of the day so far is LIXT stock. Short after the market opened, shares of LIXT were holding strong with a 100% gain for the day. This brings its five-day gain to over 135%, which is no small feat whatsoever. While many large gains occur without news, Lixte Biotechnology made an exciting announcement during premarket trading. 

The company shared the results of preclinical studies concerning its LB-100 compound, which is its lead asset. LB-100 is a protein phosphatase (PP2A) inhibitor and can be used as a cancer treatment. In the study at the China Medical University and Hospital in Taiwan, the therapy resulted in an improved response for a range of cancers. 

“Recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers. Unfortunately, most cancer patients do not respond to immunotherapy. There are widespread efforts to find pharmacologic and/or immunologic ways to turn unresponsive (‘cold’) tumors into responsive (‘hot’) tumors.” 

The CEO and Founder of Lixte, John S. Kovach, M.D.

This is big news for the company and reflects its continued work on growth. While shares of LIXT stock are likely to remain highly volatile in the near future, it still could be worth adding to your list of penny stocks to watch

Castlight Health Inc. (NYSE: CSLT) 

Another big gainer so far today is CSLT stock, pushing up by over 24% during morning trading. This brings its five-day gain to over 33% which is an impressive move for the healthcare company. If you’re not familiar, Castlight is working to make the healthcare system easier to navigate by offering a digital platform. 

[Read More] 3 Penny Stocks To Watch Under $1 That Are Moving Right Now

It is partnered with several Fortune 500 companies to offer healthcare plans with a better and easier buying experience. Big news came out during premarket trading today when the company announced a business combination with Vera Whole Health Inc. Vera is a provider of advanced primary care and owns clinics, provides health care, and has several strategic industry partnerships under its belt. 

“We believe the combined company has a unique opportunity to deliver large scale innovation to the commercial customer segment and accelerate the restructuring of the healthcare market to a stronger focus on value.” 

Ron Williams, the Chairman of Vera

The deal, worth around $370 million has already been unanimously approved by the Board of Directors at Castlight. With this big news in mind, will CSLT be on your penny stocks watchlist this month? 

Penny_Stocks_to_Watch_Castlight Health (CSLT Stock Chart)

Senseonics Holdings Inc. (NYSE: SENS) 

With a 9% gain at midday on January 5th, SENS stock is once again in the public eye. If you’re not familiar, Senseonics is a biotech company that we have covered numerous times in the past few months. It operates in the medical tech industry through the development of continuous glucose monitoring systems or CGMs. These systems are used in those who have diabetes, and offer a more efficient way to track blood sugar. Among its products are the Eversense and Eversense XL. These are inserted under the skin as a small sensor and can communicate with smartphones. 

Only a day ago, the company announced several business updates. In the update, the company stated that for the full 2021 year, it expects revenue to come in between $12 and $15 million. Additionally, the company stated that it is working on plans with Ascensia Diabetes Care for its 180-day CGM system. 

“We understand that the FDA is at full capacity managing the backlog of COVID-19 related filings creating longer than expected review timelines. We are confident a decision regarding approval of the 180-day system will be made in the coming weeks as the FDA continues to clear out the backlog.

In 2021 we integrated operations and coordination activities with our commercial collaborator Ascensia Diabetes Care. A thoughtful go-to-market strategy is being designed to target a smooth transition to the 180-day system.” 

f Senseonics, Tim Goodnow, Ph.D.

In the U.S. and globally, diabetes affects millions and has a large clinical unmet need. With systems like Eversense, Senseonics hopes to capture a part of this market. So whether this makes SENS stock worth buying or not is up to you. 

Penny_Stocks_to_Watch_Senseonics

Which Penny Stocks Are You Buying Right Now?

With so many penny stocks to choose from, finding the best ones to buy all comes down to knowing where to look.

[Read More] 4 Top Penny Stocks Analysts Say To Buy Now & Targets Up To 408%

Although it can be challenging to do so, there are hundreds of penny stocks that could be worth watching. But, investors should have a thorough and consistent understanding of their own trading style. Considering that, which penny stocks are on your watchlist right now?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post Best Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Spread & Containment

VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…

By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
Business Update
FORTRESS Trial Fully Enrolled; Topline Results in September 2022
On…

Published

on

By David Bautz, PhD

NASDAQ:VIRI

READ THE FULL VIRI RESEARCH REPORT

Business Update

FORTRESS Trial Fully Enrolled; Topline Results in September 2022

On April 28, 2022, Virios Therapeutics, Inc. (NASDAQ: VIRI) announced that it has completed enrollment of 425 fibromyalgia patients into the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1) trial, a randomized, double blind, placebo controlled study of IMC-1. The primary endpoint of the trial is reduction in pain and secondary endpoints include change in fatigue, sleep disturbance, global health status, and patient functionality (NCT04748705). An outline of the trial is shown below.

In parallel with the FORTRESS trial, Virios is continuing the chronic toxicology studies of IMC-1 in two animal species. The results of these studies are required by regulators before Virios will be allowed to dose patients for one year or more, which is the plan for the Phase 3 program. The results of the chronic toxicology studies should be known around the time of the completion of the FORTRESS trial, thus the company should be able to move into a final Phase 3 program following completion of the current study, pending positive results.

Testing Combination Antiviral Therapy for the Treatment of Long COVID

In February 2022, Virios announced a collaboration with the Bateman Horne Center (BHC) to test combination antiviral therapy for the treatment of Long COVID. Following an infection with SARS-CoV-2, the virus that causes COVID-19, approximately 30% of patients will experience symptoms that last for weeks or months, which is referred to as Long COVID. The range of symptoms varies from patient to patient, however the most commonly reported (from a recent meta analysis) were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%) (Lopez-Leon et al., 2021).

The main theories for what might be causing ...

Full story available on Benzinga.com

Read More

Continue Reading

Spread & Containment

Type-I interferon stops immune system ‘going rogue’ during viral infections

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how…

Published

on

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

Credit: Georgia Kirkos/McMaster University

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

 

They have discovered how Type I interferon (IFN) stops the immune system ‘going rogue’ and attacking the body’s own tissues when fighting viral infections, including COVID-19.

 

Their paper was published in the journal PLOS Pathogens today.

  

Senior author Ali Ashkar said IFN is a well-known anti-viral signalling molecule released by the body’s cells that can trigger a powerful immune response against harmful viruses.

 

“What we have found is that it is also critical to stop white blood cells from releasing protease enzymes, which can damage organ tissue. It has this unique dual function to kick start an immune response against a viral infection on the one hand, as well as restrain that same response to prevent significant bystander tissue damage on the other,” he said.

 

The research team investigated IFN’s ability to regulate a potentially dangerous immune response by testing it on both flu and the HSV-2 virus, a highly prevalent sexually transmitted pathogen, using mice. Data from COVID-19 patients in Germany, including post-mortem lung samples, was also used in the study.

 

“For many viral infections, it is not actually the virus that causes most of the tissue damage, it is our heightened immune activation towards the virus,” said Ashkar, a professor of medicine at McMaster.

  

First co-author of the study and PhD student Emily Feng said: “Our body’s immune response is trying to fight off the virus infection, but there’s a risk of damaging innocent healthy tissue in the process. IFNs regulates the immune response to only target tissues that are infected.

 

“By discovering the mechanisms the immune system uses that can inadvertently cause tissue damage, we can intervene during infection to prevent this damage and not necessarily have to wait until vaccines are developed to develop life-saving treatments,” she added.

 

“This applies not just to COVID-19, but also other highly infectious viruses such as flu and Ebola, which can cause tremendous and often life-threatening damage to the body’s organs,” said first study co-author Amanda Lee, a family medicine resident. 

 

Ashkar said the release of harmful proteases is the result of a ‘cytokine storm’, which is life-threatening inflammation sometimes triggered by viral infections. It has been a common cause of death in patients with COVID-19, but treatment has been developed to prevent and suppress the cytokine storm.

 

Ashkar said that steroids like dexamethasone are already used to rein in an extreme immune response to viral infections. The authors used doxycycline in their study, an antibiotic used for bacterial infections and as an anti-inflammatory agent, inhibits the function of proteases causing the bystander tissue damage.

 

Lee added: “This has the potential in the future to be used to alleviate virus-induced life-threatening inflammation and warrants further research.” 

 

The study was funded by the Canadian Institutes of Health Research.

 

-30-

 

Editors:

Pictures of Ali Ashkar and Emily Feng may be found at https://bit.ly/3wmSw0D

  

 

 


Read More

Continue Reading

Spread & Containment

mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World…

Published

on

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

Credit: Carlos Reusser Monsalvez, Flickr (CC0, https://creativecommons.org/publicdomain/zero/1.0/)

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

By March 2022, COVID-19 had caused over 450 million confirmed infections and six million reported deaths. The first vaccines approved in the US and Europe that protect against serious infection are Pfizer-BioNTech and Moderna, which deliver genetic code, known as mRNA, to the bodies’ cells, whereas Oxford/AstraZeneca and J&J/Janssen are viral vector vaccines that use a modified version of a different virus — a vector — to deliver instructions to our cells. Three vaccines are delivered as two separate injections a few weeks apart, and J&J/Janssen as a single dose.

Marit J. van Gils at the University of Amsterdam, Netherlands, and colleagues, took blood samples from 165 healthcare workers, three and four weeks after first and second vaccination respectively, and for J&J/Janssen at four to five and eight weeks after vaccination. Samples were collected before, and four weeks after a Pfizer-BioNTech booster.

Four weeks after the initial two doses, antibody responses to the original SARS-CoV-2 viral strain were highest in recipients of Moderna, followed closely by Pfizer-BioNTech, and were substantially lower in those who received viral vector vaccines. Tested against the VOCs – Alpha, Beta, Gamma, Delta and Omicron – neutralizing antibodies were higher in the mRNA vaccine recipients compared to those who had viral vector vaccines. The ability to neutralize VOCs was reduced in all vaccine groups, with the greatest reduction against Omicron. The Pfizer-BioNTech booster increased antibody responses in all groups with substantial improvement against VOCs, including Omicron.

The researchers caution that their AstraZeneca group was significantly older, because of safety concerns for the vaccine in younger age groups. As immune responses tend to weaken with age, this could affect the results. This group was also smaller because the Dutch government halted use for a period.

van Gils concludes, “Four COVID-19 vaccines induce substantially different antibody responses.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003991

Citation: van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, et al. (2022) Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 19(5): e1003991. https://doi.org/10.1371/journal.pmed.1003991

 

Author Countries: The Netherlands, United States

 

Funding: This work was supported by the Netherlands Organization for Scientific Research (NWO) ZonMw (Vici grant no. 91818627 to R.W.S., S3 study, grant agreement no. 10430022010023 to M.K.B.; RECoVERED, grant agreement no. 10150062010002 to M.D.d.J.), by the Bill & Melinda Gates Foundation (grant no. INV002022 and INV008818 to R.W.S. and INV-024617 to M.J.v.G.), by Amsterdam UMC through the AMC Fellowship (to M.J.v.G.) and the Corona Research Fund (to M.K.B.), and by the European Union’s Horizon 2020 program (RECoVER, grant no. 101003589 to M.D.d.J). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Read More

Continue Reading

Trending